, Tracking Stock Market Picks
Enter Symbol:
Achillion Pharmaceuticals, Inc. (ACHN) [hlAlert]

up 0.94 %

Achillion Pharmaceuticals, Inc. (ACHN) rated Buy with price target $20 by Brean Murray

Posted on: Tuesday,  Jan 10, 2012  2:25 PM ET by Brean Murray

Brean Murray rated Buy Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) on 01/10/2012. Previously Brean Murray rated Buy Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) on
06/02/2011., when the stock price was $7.44. Since then, Achillion Pharmaceuticals, Inc. has gained 0.94% as of 10/07/2015's recent price of $7.51.
If you would have followed the previous Brean Murray's recommendation on ACHN, you would have gained 0.94% of your investment in 1588 days.

Achillion Pharmaceuticals, Inc. (Achillion) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases. Within the anti-infective market, it focuses on the development of antivirals for the treatment of chronic hepatitis C and the development of antibacterials for the treatment of resistant bacterial infections. As of December 31, 2008, Achillion focused its efforts on advancing two late-stage preclinical candidates: ACH-1095, an NS4A antagonist for the treatment of chronic hepatitis C, being developed in collaboration with Gilead Sciences, Inc. (Gilead), and ACH-1625, a protease inhibitor also for the treatment of chronic hepatitis C. It has a pipeline of other product candidates, for which it is seeking appropriate collaborative partners. These product candidates include elvucitabine for the treatment of human immunodeficiency virus (HIV) infection and ACH-702 for the treatment of serious bacterial infections.

Our equity research department is focused on fundamental analysis across the universe of over 200 small/mid cap stocks in our five target sectors. We are committed to providing proprietary action-oriented research to our institutional clients. Small cap growth focus. Our primary area of concentration is growth stocks with market capitalization of $200 million to $5 billion. Global perspective. We are covering U.S. listed stocks for companies domiciled in the U.S., China, Europe and Latin America, with our biggest concentration in the US and China. We were one of the first banks to aggressively expand our research to China and we believe we created one of the premier research franchises in small cap, U.S. listed Chinese companies to complement our strong domestic coverage. Disciplined stock selection. Our research analysts are focused on performing extensive bottoms up due diligence on companies under our coverage by leveraging their industry and management contacts. By combining our bottoms up work with our sector views we seek to generate a consistent flow of high conviction ideas for our clients. Diversified coverage. Our areas of expertise include technology, consumer, healthcare, resources and China small cap. We provide our clients with company-specific as well as sector-specific research across our target sectors.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/10/2012 2:25 PM Buy
10.35 20.00
as of 12/31/2012
1 Week down  -7.18 %
1 Month up  2.82 %
3 Months down  -22.98 %
1 YTD up  5.11 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
6/2/2011 8:25 AM Buy
7.44 9.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy